ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement...
Deals
Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...
Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
Ikarovec, a UK‑based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a...
Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix,...
Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio
Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held...
Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline
Eli Lilly (NYSE: LLY) is in advanced talks to acquire Ventyx Biosciences for more than...
Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal
Nimbus Therapeutics announced a multi‑year research collaboration and global exclusive licensing agreement with Eli Lilly...
Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials
Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non‑exclusive clinical...
Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
Earendil Labs, the overseas subsidiary of Helixon, announced a strategic collaboration with Sanofi (NASDAQ: SNY)...
Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots
Touchstone International Medical Science Co., Ltd. (SHA: 688013) announced a strategic partnership with INSPUR Co.,...
Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets
Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with...
Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...
Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...
Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...
Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China
Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...
Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
Aspen Holdings announced a binding agreement for its wholly‑owned subsidiary Aspen Global Incorporated (AGI) to...
China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
The National Medical Products Administration (NMPA) announced that China approved 76 innovative drugs for marketing...
Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...
Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced a licensing agreement with Adlai Nortye Ltd...
NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
NeuroGen Pharma, a China‑based neurology‑focused biopharmaceutical company co‑founded by CBC Group and Mubadala in 2024,...